Mitochondrial myopathies comprise a clinically and etiologically diverse group of disorders caused by defects in cellular energy metabolism, including the breakdown of carbohydrates and fatty acids to generate adenosine triphosphate, predominantly through mitochondrial oxidative phosphorylation due to respiratory chain impairment. The wide clinical spectrum of mitochondrial myopathies ranges from severe infantile-onset multisystemic diseases to adult-onset isolated myopathies [1] .
Mitochondria are distributed throughout the muscle cell primarily in the subsarcolemmal sarcoplasm and between the sarcomeres. The ultrastructure of mitochondria can vary in different regions of the same cell, in different cells of the same fibre type and from fibre type to fibre type even in normal muscle. This can be explained in part by the plane of the section and the orientation of the mitochondria within the section. Therefore, in order to definitively identify a mitochondria myopathy using electron microscopy alone, mitochondria must be significantly altered. These changes can include "parking lot" inclusions within the mitochondria, electron dense spheroids within abnormal cristae, mitochondria with whorled cristae, the absence of cristae and mitochondria with highly condensed cristae [2] .
When abnormal findings are seen in the histochemistry or biochemical results and no significant changes in mitochondrial structure are detected, electron tomography is done on mitochondria from several areas within the cells including the subsarcolemmal sarcoplasm, the mitochondria between the sarcomeres and both type I and II myofibres. Tomographic reconstructions of the tilt series from each of the mitochondria are then Z sectioned to detect any consistent subtle changes [ Fig. 1 ].
When mitochondrial respiratory chain enzyme results are abnormal, but no pathology has been detected, immunogold labeling is done on ultrathin cryosections with antibodies against the defective enzyme [ Fig.2 and 3] [3]. Gold particle density is then determined first qualitatively and if need be quantitatively to see if the immunocytochemical results confirm the biochemistry. Double labeling experiments and further electron tomography studies are planned to see if any structural relationships can be determined between these enzymes in both normal and diseased tissues.
